Table 4 Diagnostic criteria of tested parameters and in combined analysis with CA 125 and Scc-Ag in cervical cancer patients
Tested parameters | Diagnostic criteria (%) | Cervical Cancer | ||
|---|---|---|---|---|
Squamous cell carcinoma | Adenocarcinoma | TOTAL | ||
M- CSF | SE | 69.41% | 66.67% | 69.00% |
SP | 86.00% | 86.00% | 86.00% | |
VEGF | SE | 81.18% | 86.67% | 82.00% |
SP | 76.00% | 76.00% | 76.00% | |
CA 125 | SE | 80.00% | 66.67% | 78.00% |
SP | 68.00% | 68.00% | 68.00% | |
SCC-Ag | SE | 81.18% | 53.33% | 77.00% |
SP | 74.00% | 74.00% | 74.00% | |
M-CSF + CA 125 | SE | 91.76% | 86.67% | 91.00% |
SP | 66.00% | 66.00% | 66.00% | |
M-CSF + SCC-Ag | SE | 91.76% | 86.67% | 91.00% |
SP | 66.00% | 66.00% | 66.00% | |
M-CSF + CA 125 + SCC-Ag | SE | 98.82% | 93.33% | 98.00% |
SP | 44.00% | 44.00% | 44.00% | |
VEGF+CA 125 | SE | 95.29% | 93.33% | 95.00% |
SP | 52.00% | 52.00% | 52.00% | |
VEGF+SCC-Ag | SE | 96.47% | 93.33% | 96.00% |
SP | 60.00% | 60.00% | 60.00% | |
VEGF+CA 125 + SCC-Ag | SE | 100.00% | 100.00% | 100.00% |
SP | 36.00% | 36.00% | 36.00% | |